Protalix BioTherapeutics
Latest round
- Series C
Last raised
- Jul 2005
Total raised
- $5.3M
Investors
- 3
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc.Protalix BioTherapeutics Inc. specializes in enzyme replacement therapies that cater to patients with rare genetic disorders. Founded in 1993 in Karmiel, Israel, the company became public through a reverse merger with Orthodontix, Inc. in December 2006.Protalix BioTherapeutics Inc. specializes in developing and commercializing innovative enzyme replacement therapies aimed at treating rare diseases. Their core product offerings include therapeutic proteins that address specific metabolic deficiencies caused by genetic disorders.67 mn. The company aims to launch additional enzyme replacement therapies within the next few years and is focusing on penetrating more geographic regions, particularly in Europe and Asia. The strategic goal is to make therapies accessible to a broader patient population suffering from rare diseases.
Who invested in Protalix BioTherapeutics
3 investors across 1 round
See all investors in Protalix BioTherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Jul 1, 2005
Amount
$5.3M
Investors
Questions about Protalix BioTherapeutics
Who invested in Protalix BioTherapeutics?
Protalix BioTherapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Protalix BioTherapeutics raised?
Protalix BioTherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Protalix BioTherapeutics last raise money?
Protalix BioTherapeutics's most recent round on record is a Series C, in Jul 2005.
What does Protalix BioTherapeutics do?
Protalix BioTherapeutics is a biotechnology company.
Where is Protalix BioTherapeutics headquartered?
Protalix BioTherapeutics is headquartered in Karmiel, Israel.
Which VCs invest in companies like Protalix BioTherapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Protalix BioTherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Protalix BioTherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.